Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Trinity Biotech (TRIB) Shares Outstanding (Weighted Average) (2016 - 2025)

Trinity Biotech's Shares Outstanding (Weighted Average) history spans 17 years, with the latest figure at $371.5 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 3.43% to $371.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $371.5 million, a 3.43% increase, with the full-year FY2025 number at $371.5 million, up 3.43% from a year prior.
  • Shares Outstanding (Weighted Average) hit $371.5 million in Q4 2025 for Trinity Biotech, down from $4.3 billion in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for TRIB hit a ceiling of $4.3 billion in Q2 2025 and a floor of $83.6 million in Q4 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $1.5 billion across 5 years, with a median of $1.7 billion in 2022.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): dropped 0.9% in 2021 and later surged 134.61% in 2024.
  • Tracing TRIB's Shares Outstanding (Weighted Average) over 5 years: stood at $83.6 million in 2021, then soared by 61.4% to $134.9 million in 2022, then grew by 13.46% to $153.1 million in 2023, then surged by 134.61% to $359.2 million in 2024, then grew by 3.43% to $371.5 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for TRIB at $371.5 million in Q4 2025, $4.3 billion in Q2 2025, and $359.2 million in Q4 2024.